Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public OfferingGlobeNewsWire • 01/09/26
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 01/08/26
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform ValidationSeeking Alpha • 01/08/26
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/07/26
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's WhyZacks Investment Research • 01/07/26
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk SubjectsGlobeNewsWire • 01/07/26
Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year HighInvestors Business Daily • 12/16/25
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor MutationsGlobeNewsWire • 12/16/25
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic DiseasesGlobeNewsWire • 11/08/25
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/06/25
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business UpdatesGlobeNewsWire • 11/06/25
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated DiseasesGlobeNewsWire • 10/24/25
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With NovartisZacks Investment Research • 09/16/25
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/16/25
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated DiseasesGlobeNewsWire • 09/15/25
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/25
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business UpdatesGlobeNewsWire • 08/07/25